Colorectal cancer: the latest breakthroughs

Multiple phase 3 colorectal‑cancer trials reported results in 2026, introducing new immunotherapy and targeted‑therapy combinations for metastatic and early‑stage disease.

1. The Nivolumab‑relatlimab fixed‑dose combination was compared with regorafenib or TAS‑102 in later‑line metastatic colorectal cancer (NCT05328908).
   It evaluates a novel dual‑checkpoint blockade that could offer an alternative for patients who have exhausted standard later‑line options. NCT05328908
2. Sotorasib plus panitumumab was tested against investigator’s choice in KRAS p.G12C‑mutated metastatic colorectal cancer (NCT05198934).
   Targeting the KRAS G12C mutation may provide a precision‑medicine option for a subset of patients with a historically undruggable driver. NCT05198934
3. Encorafenib plus cetuximab, with or without chemotherapy, was studied in previously untreated metastatic colorectal cancer (NCT04607421).
   The trial assesses whether adding chemotherapy to BRAF/EGFR inhibition improves outcomes for first‑line patients. NCT04607421
4. The RAPIDO trial reported results of pre‑operative induction therapy followed by surgery for rectal cancer (NCT01558921).
   Findings could reshape neoadjuvant strategies and potentially increase organ‑preserving outcomes. NCT01558921
5. Atezolizumab with or without chemotherapy was evaluated in stage III colon cancer with deficient DNA mismatch repair (NCT02912559).
   Positive results would extend immunotherapy benefits to earlier‑stage, microsatellite‑instable disease. NCT02912559
6. Adjuvant low‑dose aspirin was tested for colorectal‑cancer recurrence prevention (NCT02647099).
   If effective, aspirin could offer a low‑cost, widely accessible strategy to reduce relapse risk. NCT02647099

What to watch next

• Regulatory review and potential label updates for the Nivolumab‑relatlimab combination in later‑line metastatic disease (NCT05328908).
• FDA or EMA decisions on Sotorasib + Panitumumab for KRAS G12C‑mutated colorectal cancer (NCT05198934).
• Long‑term survival data from the Encorafenib + Cetuximab plus chemotherapy arm (NCT04607421).
• Implementation of RAPIDO trial findings into national rectal‑cancer guidelines (NCT01558921).
• Outcomes of adjuvant aspirin on overall survival and safety (NCT02647099).

🤖Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use